A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

被引：10
|
作者：
Kaddoura, Rasha [1 ]
Dabdoob, Wafer A. A. [1 ]
Ahmed, Khalid [1 ]
Yassin, Mohamed A. A. [1 ]
机构：
[1] Hamad Med Corp, Doha, Qatar
来源：
FRONTIERS IN MEDICINE | 2023年 / 10卷
关键词：
chronic myeloid leukemia; tyrosine kinase; heart failure; pulmonary arterial hypertension; QT prolongation; dasatinib; ponatinib; pleural effusion; MAJOR MOLECULAR RESPONSE; CHRONIC PHASE; CARDIOVASCULAR EVENTS; NILOTINIB; IMATINIB; HYPERTENSION; POPULATION; MANAGEMENT; DASATINIB; SAFETY;
D O I：
10.3389/fmed.2023.1163137
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.
引用
收藏
页数：19
相关论文
共 50 条
  • [21] A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
    Ozmen, Deniz
    Alpaydin, Duygu Demet
    Saldogan, Muhammed Ali
    Eskazan, Ahmet Emre
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 411 - 423
  • [22] Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib
    Breccia, Massimo
    Efficace, Fabio
    Iurlo, Alessandra
    Luciano, Luigiana
    Abruzzese, Elisabetta
    Gozzini, Antonella
    Pregno, Patrizia
    Tiribelli, Mario
    Rosti, Gianantonio
    Minotti, Giorgio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) : 623 - 628
  • [23] Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors
    Stein, Brady L.
    Smith, B. Douglas
    LEUKEMIA RESEARCH, 2011, 35 (09) : 1161 - 1163
  • [24] Intolerance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Definitions and Clinical Implications
    Pinilla-Ibarz, Javier
    Cortes, Jorge
    Mauro, Michael J.
    CANCER, 2011, 117 (04) : 688 - 697
  • [25] Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Ghanem, Hady
    Kantarjian, Hagop
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (08): : 607 - 623
  • [26] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
    Swords R.
    Alvarado Y.
    Cortes J.
    Giles F.J.
    Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
  • [27] Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review
    Santoro, Marco
    Mancuso, Salvatrice
    Accurso, Vincenzo
    Di Lisi, Daniela
    Novo, Giuseppina
    Siragusa, Sergio
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [28] Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia
    Sgherza, Nicola
    Rossi, Antonella Vita Russo
    Colonna, Paolo
    Carluccio, Paola
    Delia, Mario
    Specchia, Giorgina
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (04) : 483 - 486
  • [29] Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
    Kong, Jee Hyun
    Winton, Elliott F.
    Heffner, Leonard T.
    Gaddh, Manila
    Hill, Brittany
    Neely, Jessica
    Hatcher, Angela
    Joseph, Meena
    Arellano, Martha
    El-Rassi, Fuad
    Kim, Audrey
    Khoury, Jean Hanna
    Kota, Vamsi K.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [30] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    F J Giles
    M O'Dwyer
    R Swords
    Leukemia, 2009, 23 : 1698 - 1707
12345